DELIVERY OF GENES TO BLOCK HTLV-III EXPRESSION

人类嗜T细胞病毒-III（HTLV-III）几乎 肯定是人类表皮病的致病因子 获得性免疫缺陷综合症（艾滋病）。 艾滋病是一个主要的 美国的健康问题和预防的有效手段 疾病的传播将是非常有价值的。 这项提案的重点是中断病毒的循环， 病毒抗原在个体中的复制和表达 暴露于或已经感染了病毒。 Syntro公司利用重组DNA技术， 开发了专有的方法， 在动物中表达gnes以生产有效的疫苗。 在第一阶段，这项技术将应用于 构建基因，在表达时，应该阻止 HTLV-III在T细胞淋巴细胞中的复制。 在第二阶段， 这些结构将被放置在适当的交付 系统，并测试其功效。

Human T-cell lymphotropic virus-III (HTLV-III) is almost certainly the causal agent of the epidermic human disease Acquired Immunodeficiency Syndrome (AIDS). AIDS is a major health problem in the U.S. and an effective means of preventing the spread of the disease would be of great value. This proposal focuses on interrupting the cycle of viral replication and expression of viral antigens in individuals exposed to or already infected with the virus. Syntro Corporation, using recombinant DNA technology, has developed proprietary methods for the delivery to and expression of gnes in animals to produce effective vaccines. In Phase I of the proposal, this technology will be applied to construct genes which, upon expression, should block the replication of HTLV-III in T-cel lymphocytes. In Phase II, these constructs will be placed in the appropriate delivery system and tested for efficacy.